ES2300490T3 - Inhibidores de fosfolipasa a2 citosolica. - Google Patents

Inhibidores de fosfolipasa a2 citosolica. Download PDF

Info

Publication number
ES2300490T3
ES2300490T3 ES02786829T ES02786829T ES2300490T3 ES 2300490 T3 ES2300490 T3 ES 2300490T3 ES 02786829 T ES02786829 T ES 02786829T ES 02786829 T ES02786829 T ES 02786829T ES 2300490 T3 ES2300490 T3 ES 2300490T3
Authority
ES
Spain
Prior art keywords
acid
ethyl
chloro
alkyl
benzoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02786829T
Other languages
English (en)
Spanish (es)
Inventor
John Caedmon Mckew
Steve Yik-Kai Tam
James Donald Clark
Katherine Lin Lee
Lihren Chen
Paresh Thakker
Fuk-Wah Sum
Mark Leo Behnke
Baihua Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of ES2300490T3 publication Critical patent/ES2300490T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES02786829T 2001-12-03 2002-12-02 Inhibidores de fosfolipasa a2 citosolica. Expired - Lifetime ES2300490T3 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US33459101P 2001-12-03 2001-12-03
US33458801P 2001-12-03 2001-12-03
US33460501P 2001-12-03 2001-12-03
US334591P 2001-12-03
US334588P 2001-12-03
US334605P 2001-12-03
US41966402P 2002-10-18 2002-10-18
US419664P 2002-10-18

Publications (1)

Publication Number Publication Date
ES2300490T3 true ES2300490T3 (es) 2008-06-16

Family

ID=27502498

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02786829T Expired - Lifetime ES2300490T3 (es) 2001-12-03 2002-12-02 Inhibidores de fosfolipasa a2 citosolica.
ES07023208T Expired - Lifetime ES2401454T3 (es) 2001-12-03 2002-12-02 Inhibidores de la fosfolipasa A2 citosólica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES07023208T Expired - Lifetime ES2401454T3 (es) 2001-12-03 2002-12-02 Inhibidores de la fosfolipasa A2 citosólica

Country Status (24)

Country Link
EP (1) EP1451154B1 (enExample)
JP (1) JP4657605B2 (enExample)
KR (1) KR100973665B1 (enExample)
CN (1) CN100503566C (enExample)
AR (1) AR037684A1 (enExample)
AT (1) ATE384045T1 (enExample)
AU (1) AU2002351182B2 (enExample)
BR (1) BR0214672A (enExample)
CA (1) CA2469138C (enExample)
CO (1) CO5580763A2 (enExample)
CY (1) CY1107383T1 (enExample)
DE (1) DE60224707T2 (enExample)
DK (2) DK1892239T3 (enExample)
EC (1) ECSP045131A (enExample)
ES (2) ES2300490T3 (enExample)
HU (1) HUP0402577A3 (enExample)
IL (2) IL162052A0 (enExample)
IN (1) IN2005KO00312A (enExample)
NO (1) NO327256B1 (enExample)
NZ (1) NZ533269A (enExample)
PL (1) PL370445A1 (enExample)
PT (1) PT1451154E (enExample)
TW (1) TWI334778B (enExample)
WO (1) WO2003048122A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
TW200510305A (en) * 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
PL1685104T3 (pl) 2003-11-17 2008-03-31 Wyeth Corp Sposoby wytwarzania N-podstawionych ftalimidów
HN2004000536A (es) * 2003-12-16 2009-02-18 Wyeth Corp Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles
AR048239A1 (es) 2004-02-25 2006-04-12 Wyeth Corp Procesos para la preparacion de haluros de aril- y heteroaril-alquilsulfonilo e intermediarios de sintesis de los mismos
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
AR053410A1 (es) * 2004-08-19 2007-05-09 Wyeth Corp Proceso para la sintesis de indoles n-alquilados c-2, c-3 sustituidos. compuestos intermediarios
ATE473735T1 (de) 2005-04-13 2010-07-15 Astion Dev As Beta-2 adrenoceptor agonisten zur behandlung von bindegewebserkrankungen der haut
GT200600228A (es) 2005-05-27 2006-12-26 Inhibidores de la fosfolipasa a2 citosolica
TW200728262A (en) * 2005-07-21 2007-08-01 Wyeth Corp Process for the synthesis of sulfonyl halides and sulfonamides from sulfonic acid salts
MX2008005666A (es) 2005-11-03 2009-03-02 Ilypsa Inc Compuestos multivalentes de indol y uso de los mismos como inhibidores de fosfolipasa-a2.
FR2899471A1 (fr) * 2006-04-06 2007-10-12 Pasteur Institut Utilisation d'au moins un inhibiteur de la phospholipase a2 cytosolique comme medicament pour le traitement des maladies respiratoires
WO2007140317A2 (en) * 2006-05-26 2007-12-06 Wyeth Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis
WO2008055146A2 (en) * 2006-10-31 2008-05-08 Wyeth Formulations of phospholipase enzyme inhibitors
BRPI0718066A2 (pt) * 2006-10-31 2013-11-05 Wyeth Corp Composição farmacêutica; forma de dosagem farmacêutica; processo para preparar uma composição farmacêutica;e produto.
WO2008120818A1 (ja) * 2007-03-29 2008-10-09 Asubio Pharma Co., Ltd. ｃＰＬＡ２阻害活性を有するインドール誘導体およびその用途並びに製造方法
KR101269393B1 (ko) 2008-04-28 2013-05-29 아사히 가세이 파마 가부시키가이샤 페닐프로피온산 유도체 및 이의 용도
CA2777782C (en) * 2009-10-15 2016-06-28 Children's Medical Center Corporation Sepiapterin reductase inhibitors for the treatment of pain
EP2614144B1 (en) 2010-09-08 2015-07-22 Twincore Zentrum für Experimentelle und Klinische Infektionsforschung GmbH Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079374C (en) * 1991-09-30 2003-08-05 Merck Frosst Canada Incorporated (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5994398A (en) * 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
HRP20000552A2 (en) * 1998-02-25 2001-04-30 Genetics Inst Inhibitors of phospholipase enzymes
AU765427B2 (en) * 1998-02-25 2003-09-18 Genetics Institute, Llc Inhibitors of phospholipase enzymes

Also Published As

Publication number Publication date
HUP0402577A3 (en) 2011-05-30
DK1892239T3 (da) 2013-03-25
CN1617855A (zh) 2005-05-18
ATE384045T1 (de) 2008-02-15
AU2002351182B2 (en) 2009-01-15
WO2003048122A3 (en) 2003-09-18
AR037684A1 (es) 2004-12-01
HK1065799A1 (en) 2005-03-04
KR20050044661A (ko) 2005-05-12
CN100503566C (zh) 2009-06-24
KR100973665B1 (ko) 2010-08-04
EP1451154B1 (en) 2008-01-16
JP2005515997A (ja) 2005-06-02
DE60224707D1 (de) 2008-03-06
CO5580763A2 (es) 2005-11-30
ECSP045131A (es) 2004-07-23
NO327256B1 (no) 2009-05-25
DK1451154T3 (da) 2008-05-19
ES2401454T3 (es) 2013-04-19
CY1107383T1 (el) 2012-12-19
DE60224707T2 (de) 2009-02-26
IL162052A (en) 2013-04-30
EP1451154A2 (en) 2004-09-01
CA2469138A1 (en) 2003-06-12
PL370445A1 (en) 2005-05-30
JP4657605B2 (ja) 2011-03-23
HK1113798A1 (en) 2008-10-17
IL162052A0 (en) 2005-11-20
NZ533269A (en) 2006-03-31
TW200301695A (en) 2003-07-16
WO2003048122A2 (en) 2003-06-12
BR0214672A (pt) 2004-10-19
TWI334778B (en) 2010-12-21
PT1451154E (pt) 2008-04-21
AU2002351182A1 (en) 2003-06-17
HUP0402577A2 (hu) 2005-03-29
IN2005KO00312A (enExample) 2015-08-14
NO20042679L (no) 2004-06-25
CA2469138C (en) 2012-04-17

Similar Documents

Publication Publication Date Title
ES2300490T3 (es) Inhibidores de fosfolipasa a2 citosolica.
US6797708B2 (en) Inhibitors of cytosolic phospholipase A2
US7906548B2 (en) Methods for the use of inhibitors of cytosolic phospholipase A2
US6500853B1 (en) Inhibitors of phospholipase enzymes
US7713964B2 (en) Methods for treating asthmatic conditions
KR100955015B1 (ko) 2ｈ-프탈라진-1-온 및 이것의 사용 방법
ES2262817T3 (es) Agonistas beta-3 oxindol 3-sustituidos.
CA2717750C (en) Azetidine derivatives
US20080009485A1 (en) Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis
CN102803235A (zh) 选择性调节cb2受体的化合物
CA2607857A1 (en) Inhibitors of cytosolic phospholipase a2
US7101875B2 (en) Methods for treating arthritic disorders
US6635771B2 (en) N-benzhydryl indole compounds
EP1892239B1 (en) Inhibitors of cytosolic phospholipase A2
RU2337906C2 (ru) Ингибиторы цитозольной фосфолипазы а2
HK1065799B (en) Inhibitors of cytosolic phospholipase a2
HK1113798B (en) Inhibitors of cytosolic phospholipase a2
UA77472C2 (en) Inhibitors of cytosolic phospholipase a2